Consequences of cystic fibrosis transmembrane regulator mutations on inflammatory cells

Sandra Grumelli1, German A Islan2 and Guillermo R Castro2 *

1Center of Investigations in Medicine of Respiratory, Universidad Católica de Córdoba, Córdoba, Argentina
2Nanobiomaterials Laboratory, Institute of Applied Biotechnology (CINDEFI, UNLP-CONICET, CCT La Plata), Department of Chemistry, School of Sciences, Universidad Nacional de La Plata, Calle 47 y 115, 1900 La Plata, Argentina

Abstract

Recent studies in cystic fibrosis (CF) transmembrane regulator (CFTR) mutations and function have shed light on its involvement in disease progression. The extent of cell and tissue distribution of CFTR facilitates systemic dysfunction of ion transport in patients carrying a mutation in CFTR, however, its incidences as co- founding risk factor to develop other diseases is not well studied. In this review we differentiate the dysfunctions driven by CFTR mutations in cell of the immune system and their role in CF progression and examine the types of medical treatments available to patients up to date.

Introduction

Identification of mutations associated to Cystic Fibrosis (CF) was initially searched in lung cell, epithelia, mucus goblet cells, etc. However, recently it has become more obvious that cystic fibrosis transmembrane regulator (CFTR) mutation on immune cells produces dysregulation in the lung even before infections occur. In this review we summarized how affects immune cells response and how it has changed the treatments of CF.

Types of mutations of the cystic fibrosis transmembrane regulator

Cystic Fibrosis is an autosomal life threatening recessively inherited human disease assigned to the Mendelian Inherited disease in Man (MIM) number 219700. Clinical manifestations of the CF pathology are mainly associated to the impairing functions of gastrointestinal and respiratory tracts. Pathological characteristic of CF are commonly associated to exocrine pancreatic insufficiency, recurrent lung infections, intestinal manifestations and "salty" sweat. Also secondary pathologies such as liver disease, pancreatitis, and diabetes were observed in some patients [1].

The frequency of CF is in average 1 in 2,500-3,000 live births, meaning about 80,000 people worldwide and about 1,000 new cases of CF are diagnosed yearly. However, the probability of CF frequency is related to the geographic distribution and ethnicity. In Europe, the highest prevalence of CF is observed in Ireland (1/1,700) and the lowest in Finland (1/7,700). In the United States, the birth frequency

Correspondence to: Guillermo R. Castro, Nanobiomaterials Laboratory, Institute of Applied Biotechnology (CINDEFI, UNLP-CONICET, CCT La Plata), Department of Chemistry, School of Sciences, Universidad Nacional de La Plata, Calle 47 y 115, 1900 La Plata, Argentina, Tel: ++54-221-4833674; ++54-221-4833132; E-mail: grcastro@gmail.com

Key words: cystic fibrosis, CFTR-deficiency, CF-immune response, antibiotic therapies, microbiome maintenance, and gene therapy

Received: April 15, 2016; Accepted: June 06, 2016; Published: June 10, 2016
affected of CF is 1/2,500 births for Caucasians of Northern European descent, 1/3,500 for Hispanics, 1/15,100 for Africans and 1/35,000 for Asians. The life expectancy of CF patients is increasing based on novel therapeutic strategies and novel technologies. During the 80’s the patient average life expectancy was about 14 years, increased during the 90’s to around 18 years and today is in between 30 to 40 years old [2]. However, there are huge differences between the patient’s life expectancies in developed and undeveloped countries.

The CF disorder is produced by mutations in a gene located in the human long arm of chromosome 7 (it is Cystic fibrosis Transmembrane Regulator (CFTR) protein associated to abnormal CFTR protein mainly expressed in secretory epithelial cells. The CFTR is mainly located in cytosol (about 85%), meanwhile the other 15% belongs to the lumen and ER membrane. From the structural point of view, the CFTR possess three different types of domains: two membrane spanning domains, one regulator, and two nucleotide binding domains for cAMP and cGMP [3-4]. Up today, 1997 mutations have been identified in the CFTR gene reported by the Cystic Fibrosis Data Base (http://www.genet.sickkids.on.ca/CFTR/).

The large amounts of CFTR mutations are related to sequence and/or promoter variation, missense and non-sense, sequence variation, frame in/del, large in/del, splicing and unidentified types involving mutations in different exons and/or introns. From physiological and therapeutic point of view, the mutations were identified roughly into six classes [5] (Table 1).

The types 1 to 3 are most prevalent mutations and related to pancreatic insufficiency, meanwhile types 4 to 6 are not. Particularly, class 2 is the dominant CF-mutation in Caucasians affecting 86% CF alleles. The class 2 mutation is based on the absence of three nucleotides coding for phenylalanine amino acid in the 508 position of the encoded protein named F508del [1]. Also, the frequency of F508del is variable according to the population. For example, F508del is affecting the 82% of CF patients in Denmark and 32% in Turkey [5].

**CFTR function**

The basis of CF pathology is linked directly to malfunction of the Cystic Fibrosis Transmembrane Regulator (CFTR) protein associated to the trans-epithelial chloride conduction, but also implicated in the transport of other molecules through the membrane [6,7]. The physiological role of CFTR is complex because intervenes in the transport of other molecules like Renal Outer Medullary potassium channel (ROMK K+), Epithelial sodium channel (ENaC), 1-exchanger, cellular membranes against concentration gradients [8-10]. The CFTR protein is a channel member of the ATP-binding cassette superfamily (ABC transporters) commonly described as ATP hydrolyzing proteins able to transport different molecules through cellular membranes against concentration gradients [11]. The CFTR transporter is classified as ABCC7 found in almost any form of life [12].

**Regulation of the CFTR**

The mechanism of CFTR regulation is very complex (Figure 1) and involves different regulatory levels such as phosphorylation and dephosphorylation, posttranslational modifications, e.g. glycosylation, to the interaction with membrane and cytoplasmic proteins, and check point of appropriate CFTR structure. The phosphorylation/dephosphorylation mechanisms on NBD domains of the CFTR are required to activate and deactivate the chloride ion channel a cAMP-dependent manner [13]. The phosphorylation of CFTR by PKA is catalyzed by the subunit PKA-cat and regulated by the subunit PRKAR2A through the villin-2 protein (also known as Ezrin) who anchors PKA-cat. Villin-2 interacts with the NBD domain of CFTR mediated by the regulatory protein E3KARP (also named as NHERF-2) containing a PDZ binding motif. The PDZ motif of E3KARP possess high affinity for the PDZ counterpart motif located at the carboxylate terminus of NDB domain and also Annexin II protein complex, involved in the interaction to enhance the phosphorylation of CFTR [14]. On the other side, activation of PKA mediated by adenosine also induced the activity of phosphodiesterase 4D (PDE4D) catalyzing the conversion of cAMP into AMP. The AMP product activates 5’AMP activated protein kinase (AMPK) acting a negative effector by phosphorylating the NDB of CFTR and reducing the chloride ion transport [15]. Also, protein phosphatases type II (PP2A and PP2C) dephosphorylates CFTR causing inhibition of ion transport [16]. Besides, other protein complexes like the syntososomal-associated 23 kDa protein (known as SNAP-23) syntaxin 1A interfere sterically with the CFTR transporter reducing the chloride ion transport [17].

Table 1. Classification and description of cystic fibrosis mutations.

| Class | Mutation  | Cellular and/or molecular phenotype |
|-------|-----------|----------------------------------|
| I     | Trp1282X, and Gly542X | Absent CFTR synthesis due to non-sense mutations, or frame shift mutations, or abnormal mRNA splicing. |
| II    | Phe508del | Defective intracellular processing of CFTR with less than normal amounts of CFTR protein at the apical plasma membrane. |
| III   | Gly551Asp | Defective regulation of CFTR channels at the apical plasma membrane. |
| IV    | Arg117His | Defective transport of anions through CFTR channels at the apical plasma membrane. |
| V     | 3849+10kbC>T | Reduced production or processing of normal CFTR. |
| VI    | Gin1412X  | Altered apical membrane residence time of CFTR channels with truncated c-termini. |

EJB50, another protein with PDZ binding domain, is the protein
bridge between Beta-2 adrenergic receptor (ADRB2) and CFTR. However, the complex formation with the beta-2 adrenergic receptor is inhibited when the PKA phosphorylates the CFTR. The ADRB2 is a receptor for the binding of epinephrine and linked to the calcium ion channel, which is functional for smooth muscle relaxation and bronchodilation [20]. Another way to inhibit the CFTR is by suppressing the activity of PKA and adenylate cyclases depressing the cAMP in the cell by members of G-protein -I family cascade [21].

The regulation of the CFTR function involves also the interaction of the transporter with cytoplasmic proteins like NHERF-1 and regulating the ion flux at the gateway [22]. In addition, the endoplasmatic reticulum (ER) is working as “custom” of the CFTR transporter checking proper protein folding and glycosilation. Proteolysis of abnormal CFTR transporter was suggested by tagging the protein with an “adaptor ligase” activating the ubiquitin - proteasome degradative pathway associated to ER named as ERAD [23,24].

On the other hand, CFTR regulation is not only made in the cell cytoplasm but also in the cell membrane. CFTR was phosphorylated by Protein Kinase C-ε (epsilon) in order to stabilize the transporter in the membrane and also to prime the PKA. However, the PKC-ε is part of the protein complex pathway involving soluble carrier family 9 (member 3 regulator 1), guanine nucleotide binding protein -polyphemus2-like 1 [25,26].

**CFTR mutations on inflammatory cells**

It is thought that CF is an epithelia based disease; however CFTR dysfunction of immune cells plays a causal role in lung infection as CFTR mutations predisposes to Th2 bias that differentiates CF immune response from the rest of the lung diseases, and this precedes lung infections (Figure 2). In this review we will focus on the changes produced by CFTR mutations on immune cells [27,28].

**Lymphocytes**

In order to achieve homeostasis after an inflammatory process has been initiated in response to cytokine stimulation, T helper’s naïve (Th0) cells are differentiated along Th1/Th2 and Th17/ T regulatory (Treg) lineages, which suppress the inflammation. Recently was shown that Tregs from patients with CF, or from knock out CFTR mice (CFTR’), are impaired in suppressing conventional T effector cells, an

---

**Figure 1.** Signaling pathways involved in CFTR regulation. Beta-2 adrenergic receptor (ADRB2), phosphatases type II (PP2A), Protein Kinases A (PKA), subunit PRKAR2A, Protein Kinases C (PKC), mitogen activated protein kinases (MAPKs) receptor for the binding of epinephrine (ADRB2), syntaxin 1A (STX1A), Phosphatidyl inositol 3 kinase (PI3K). Nuclear Factor-κ B (NFκB), nuclear factor erythroid 2–related factor 2 (Nrf2), Toll like receptor 4 (TLR4), lipopolysaccharide (LPS), macrophage inducible protein-2 (MIP-2) by p38. Macrophage metallo elastase 12 (MMP12), butyrate dehydrogenase type-2 (BDH2), iron carrier protein NGAL, heme oxygenase1 (HO1), [epithelial Na channel transgenic mouse (EnaC). Pointed arrows means activation and bold arrows inhibition.

**Figure 2.** Schematic representation of lung immune response biases. Chronic obstructive pulmonary disease (COPD). Cystic fibrosis (CF).
effect that was enhanced by *P. aeruginosa* infection. The loss of Tregs in CF affected memory, but not naïve, Tregs and manifested gradually with disease progression, confirmed by a positive association between lung function, measured by forced expiratory volume (FEV1%), and number of Tregs present in peripheral blood of CF patients [29,30].

Murine model of CF confirmed impaired Tregs down regulation of Th2 cells; CFTR-/- mice had enhanced intracellular Ca²⁺ flux in response to T cell receptor (TCR) activation on T effector cells, higher interleukin (IL) 4, IL-13, IgE and IgG1, this prominent Th2 bias correlated with higher nuclear NFAT level than their wild type control littersmates (CFTR+/-). There was also an impaired inactivation of these cells by Tregs and defective Th1 response, indicating the CFTR importance to maintain the Th1/Th2 balance [30-32].

Th2 bias assessed in CF patients preceded the *P. aeruginosa* infection in a study conducted in 75 subjects, which proved a positive association among secretion of IL-5 with number of neutrophils in broncho-alveolar lavage (BAL) of CF subjects. There was a significant association among computed tomography changes and cytokines and chemokines assessed for Th2 bias (IL5, IL13, TARC/CCL17) and Th17 (IL17A, IL6, IL1β, IL8) [33]. However, IL-13 seems to play a greater role then IL-4 in CF since lung parenchyma leukocytes produce high IL-13, IL-10 and RANTES levels and weakly IL-17, when exposed to *Pseudomonas* sp.

The signaling path that determines Th2 bias includes the purinergic receptor (P2Y2) which senses ATP level secreted in a CFTR dependent manner in the first stage of inflammation upon infection (Figure 3) [34,35]. Upon viral infections knockout mice in P2Y2 had increased IL-6, reduced ATP, IL-12, and CD4⁺, CD8⁺ T cells and dendritic cell, with defective viral clearance and predominant Th2 bias but normal levels of IP10 and MIP-3 as represented in Figure 3 [35].

In addition to Th2 bias, the binding of IL-13 to its receptors on Th17 cells down regulates IL-17A production (Figure 3) and its neutralization is necessary for significant IL-17 augmentation, this increase was a lesser amount with IFN-γ or IL-4 neutralization [27,28]. Consequently, T cells specific for *Pseudomonas aeruginosa* and *Aspergillus fumigatus*, obtained from patients with CF, displayed significantly higher IL5 and IL17A mRNA expression and TARC/CCL17 in patients that developed *P. aeruginosa* infection within 24 months. High expression of these cytokines/chemokines in CF airways preceded infection with *P. aeruginosa* demonstrating an intrinsic predisposition of Th0 cells to differentiate to Th17 phenotype although they had normal capacity for Th1 and Treg differentiation [33,36,37].

Th17, IL-17⁺ neutrophils, γδT and natural killer T cells (NKT) are increased in newly diagnosed CF subjects with BAL fluid neutrophilia [38]. Th17 cells from CF subjects had an antigen-specific response rather than a merely nonspecific mitogen-induced IL-17 release. Within the CD4⁺IL-17⁺ population there were some expressing IL-22 with a higher proportion of CD45RO⁺ TCRαβ⁺ cells compared with...
IL-22 cells, suggesting a role for IL-22 in maturation of the adaptive response to develop memory T-cell fraction [27]. The mechanism of Th17 production involves indole-amine 2,3-dioxygenase (IDO), since in murine and human CF dysfunctional IDO activity correlated with imbalanced Th17/Treg cell responses to *Aspergillus fumigatus*, that was restored by genetic rescue of IDO production as represented in Figures 1 and 2 [39].

Tregs are essential to maintain immune system homeostasis by suppressing T effector cells harnessing tissue destruction; in healthy humans, fungus specific CD4+CD25+CD127 Foxp3+ Treg are strongly expanded in peripheral blood and possess phenotypic, epigenetic and functional features of thymusderived Treg. However, for *Aspergillus sp.*, the strong Treg response contrasts with minimal conventional Tcell memory, indicating selective Treg expansion as an effective mechanism to prevent inappropriate immune activation in healthy individuals. By contrast, in subjects with *Aspergillus sp.* allergies, specific Th2 cells were strongly expanded despite the presence of specific Treg [40]. Upon *P. aeruginosa* infection CFTR+ mice had reduced Treg count, while in CF patients there was impaired Treg suppression of Th2 inflammation, indicating the same impairment that underlay *Aspergillus sp.* infection [30].

It has emerged autoimmune particularly overt in cystic fibrosis mice lacking invariant natural killer T (iNKT) cells which play a role to control autoimmune diseases triggered by a ceramidedemidated induction of cell death in CF, and although suppression of the autoimmune response by iNKT cells is beneficial, IL-17+ iNKT cells attract macrophages and neutrophils to CF lungs resulting in chronic inflammation. Genetic deletion of iNKT cells in cystic fibrosis mice prevents inflammation in their lungs [41].

In summary, CFTR deficiency is highly disruptive of T cells function promoting an exaggerated Th2 response, reduced Treg population and enhanced Th17 response, this increases neutrophils recruited by IL-17 to the lung, which are a major cause of alveoli destruction associated with lung decay in CF.

### Macrophages

Cystic fibrosis patients are susceptible to infections of opportunistic extracellular or intracellular pathogens, the appropriate immune response is different for each type of infection and the capacity to resolve it favorably depends on the CFTR impairment of the immune cell type involved. CF patients with mucoid *P. aeruginosa* chronic infections have a positive correlation between lung function and interferon IFN-γ produced by CFTR/- peripheral blood mononuclear cells. In contrast, IL17A levels tended to correlate negatively with lung function [42]. IFNγ induces phagocytosis binding autophagy protein p62, which promotes the double membrane vacuolization around the infecting bacteria increasing traffic to the lysosomes (Assani et al., 2014). IFNγ also up regulates monocytes the chemo-attractant protein1 (MIP-1), tumor necrosis factor α (TNFa) and IL6 production and down regulates IL10 expression in infected macrophages [42].

Macrophages with CFTR depletion from membrane lipids raft, caused by second hand smoke, lypo polysaccharide (LPS) or alginate produced by *F. aeruginosa*, or mutations, have inhibited their phagocytic capacity [44,45]. CFTR/- macrophages exhibit aberrant acidification of phagolysosomes and do not kill internalized microorganisms as effectively as wild-type cells do [46].

Bacterial LPS produces uncontrolled toll like receptor 4 (TLR4) signals through phosphatidil inositol 3 kinase (PI3K), activating Akt, which inactivates the Nuclear Factor-κ B (NF-κ B) repressor (GSK3β) inducing nuclear transcriptions factor (NF-κ B), p38 and mitogen activated protein kinases (MAPKs) activity transcribing TNF-α, IL-6,IL-8 and macrophage inducible protein-2 (MIP-2) and repressing of scaffold protein CAV1. CFTR/- macrophages have upregulated phospholipase A2a (PLA2a) activity and IL-6 secretion, which is lethal upon *P. aeruginosa* infection. IL-6 was decreased in PLA2a/- mice without affecting IL-1β, or TNF-α [47-49].

The uncontrolled TLR4 signaling is due to high microRNA199a5p levels, which are PI3K/AKTdependent. However, PI3K/Akt activation does not regulate phagocytosis; rather Akt/miR199a5p/CAV1 pathway promotes migration of monocytes and neutrophils responsible of hyperinflammation, tissue damage and lung decay [49,50].

LPS triggers inflammatory response in the reticulum (Figure 1) down regulating the short chain butyrate dehydrogenase type-2 protein and up-regulating the expression of iron carrier protein NGAL and stress inducible heme degrading enzyme heme oxygenase1 (HO-1) leading to iron liberation from macrophages [51]. LPS and INF-γ improves macrophages killing of *P. aeruginosa* inducing scaffold protein Ksr1 (a ceramide-activated, serine-threonine kinase) that recruits heat shock protein 90 (Hsp90) and nitrogen oxide (NO) synthase (iNOS) to form a membrane complex that produces NO and nitric peroxide essential for bacterial clearance, as genetic deletion of Ksr1 impairs bacterial clearing and causes mouse lethality to *P. aeruginosa* infection [52-54].

*Mycobacterium abscessus* is an intracellular macrophage pathogen that has emerged as a risk factor for CF patients. *M. abscessus* infection is accompanied by increased HO1 precursor of bilirubin and biliverdin regulators of reactive oxygen species (ROS). The HO-1 is induced by p38 MAPKdependent, as p38 inhibitors suppressed HO1 and inhibited *M. abscessus* growth inside macrophages. Furthermore, inhibiting HO1 using HO1 siRNA or the HO1 upstream signaling molecule, nuclear factor erythroid 2–related factor 2 (Nrf2), with siRNA results in similar inhibition of *M. abscessus* [55]. Nrf2 regulates a cytoprotective response to counteract oxidative stress–induced essential for clearance of intracellular pathogens like *M. abscessus* but a fine equilibrium has to be maintained since decrease in Nrf2 signaling is associated with the progression of diseases driven by oxidative stress response. This indicates that targeting Nrf2 can improve innate antibacterial defenses, and restore corticosteroid responses in chronic lung diseases [56].

Viral infection of mice heterozygous in CFTR mutation (CFTR+/−) showed that TGFβ dependent production of IL6 by macrophages late in infection prevents acute lung injury from influenza A virus infection. This effect in CFTR−/− mice was associated with post-infection production of TGFβ with higher IL6 and alveolar macrophages at 6 days postinfection that did not occur in WT mice. Neutralization of β-TGF reduced IL-6 secretion but IL6 neutralization did not affect BAL macrophages and neutrophils numbers, rather it attenuated the CXCL1/KC response in both strains, and reduced IFNγ production in WT mice. All this is indicating that IL-6 is involved in activation of macrophages rather than recruitment, and the IFNγ/IP10/MMPI2 pathway is essential for acute lung injury as recently the relevance of MMP12 in lung injury of CF patients was assessed with the β epithelial Na+ channel transgenic mouse (βENaCtG) that produces dehydrated airway and increased secretion of activated MMP12 (Figure 3). They also showed elevated MMP12 activity on the surface of airway macrophages in BAL from βENaCtG mice and patients with CF. Further, they report MMP12 polymorphism associated with severity...
of CF, indicating a new mechanism of emphysema triggered by ionic dysregulation rather than cigarette smoke exposure [57-59].

In summary, this data suggest that macrophages may be driving lung decay in CF through activation of MMP12.

**Neutrophils**

Patients with CF display exaggerated neutrophilic responses to pathogens and their neutrophils have an impaired capacity to undergo apoptosis, even prior to migration to the lung, as shown for *Pseudomonas* colonized F508 homozygote CF blood neutrophils. The blood inflammatory markers interleukin beta (IL1β), Creative protein (CRP) and myeloperoxidase (MPO), are elevated during recruitment of neutrophils to the lung [60].

Neutrophils roll in the blood stream and adhere to the vasculature of the injured site where the cytokines and chemokine are being produced, after chemotaxis they egress to the lung epithelia. Neutrophils carrying CFTR mutation G551D have significantly higher expression of active adhesion molecule CD11b and of CD63 on monocytes, ex vivo exposure to ivacaftor of blood cells from G551D, but not F508del and healthy subjects, resulted in changes in CXCR2 and CD16 expression on neutrophils [61].

Neutrophils recruitment to the lung is dependent of IL-17, CXCL1/KC and IL-1 production [33,62]. Epithelia cells that have been injured signal through heparin A3, a chemotactic eicosanoid that mediate the transepithelial passage of neutrophils, in response to infection (Figure 3). Neutrophil-dervied leukotriene B4 signaling is generated by migrated neutrophils augmenting the initial heparin A3 and collectively coordinate an effective neutrophil transepithelial migratory response [63].

Decreased IL17 and the homolog to IL1 (IL8 in mice) results from the deficiency of calcium activated chloride channel regulators (CLCA3-4) with reduced neutrophil infiltration into the bronchoalveolar space during bacterial infection, compared to wildtype mice [64]. Glycosaminoglycans influence the chemokine profile of the CF lung by binding IL-8 and protecting it from proteolytic degradation. IL-8 is maintained in an active state by this glycan interaction increasing neutrophil infiltration into the lungs [65]. IL-8 recruits and activates neutrophils through G-couple chemokine receptor (CXCR1), this is regulated through elastase cleavage of the receptor mediated by PAR-2, which co-localizes with CXCR1.

Neutrophils egress from the microvasculature is mediated by VAP-1/SSAO, an endothelial bound adhesion molecule with amine oxidase activity. Adherence is induced by CXCL1/KC and inhibition of VAP1/SSAO also dampens migration of neutrophils to the lungs in response to LPS [66]. Upon arrival to the lung neutrophils interact with epithelial cells through secretion of proteins S100A8, S100A9 and S100A12 which binds TLR4 and the receptor for advanced glycation end-products (RAGE) stimulating mucin production from epithelial cells (Figure 3) [67]. C reactive protein (CRP) generated in inflamed tissues inhibits neutrophil apoptosis via a mechanism involving activation of FcRIII (CD16) and P3K. Inhibitor of P3K, LY294002, increased CF neutrophils apoptosis in 50%, similar to normal patients’ neutrophil apoptosis [68]. In addition to prolonged life span, that impairs inflammation resolution, neutrophils carrying CFTR mutations have significantly higher expression of active CD11b and compromised phagocytosis, which predispose CF lungs to infection [61,69].

In the tissue, neutrophils arrest *P. aeruginosa* growth by chemotactic effect undergoing a respiratory burst following C3b and Fc receptor activation with extracellular release of ROS such as O₂⁻, H₂O₂ and NO, consuming large amounts of O₂ forcing the bacteria to enter into anaerobic metabolism [70-72]. In addition, hypochlorous acid produced by this mechanism is reduced by MPO oxidizing glutathione to glutathione sulfamides [73].

*P. aeruginosa* release less granule containing MPO, neutrophil elastase (NE) and extracellular DNA compared with control patients and this is associated with reduced activity of the low molecular weight GTP-binding protein Rab27a due to higher intracellular Cl, lower Mg²⁺ and reduced degranulation and killing ability [74]. Degranulation of neutrophils by gram-negative bacteria is mediated by galectin-9 (Gal9) interaction with T cell immunoglobulin and mucin domaincontaining molecule 3 (TIM-3). TIM3/Gal9 signaling modulates cytosolic Ca²⁺ levels and enhances NADPH activity that is essential for ROS production [75].

Over all, the reduced apoptosis, degranulation and killing ability caused by the ionic imbalance of CFTR mutation together with increased adhesiveness leads to neutrophilia in CF lungs (Figure 3) that negatively correlates with their FEV1 [60].

**CF Infections**

Colonization by bacteria may synergize, amplify, or trigger pathways of tissue damage; the most common infection in cystic fibrosis patient is *P. aeruginosa*. However, many other opportunistic pathogens are also able to colonize the lung of these patients, infections that ultimately leads to respiratory failure.

**P. aeruginosa infection**

The growth rate of *P. aeruginosa* within CF lungs inversely correlates to the concentration of neutrophils surrounding the bacteria. A growth limiting effect on *P. aeruginosa* by neutrophils was also observed in vitro, where this limitation was alleviated in the presence of the alternative electron acceptor nitrate. The finding that *P. aeruginosa* growth patterns correlate with the number of surrounding neutrophils points to a bacteriostatic effect by neutrophils via their strong O₂ consumption and release of ROS upon activation, which slows the growth of *P. aeruginosa* in infected CF lungs [72]. Never the less *P. aeruginosa* has the ability to circumvent this bactericidal mechanism producing kynurenine an oxygen peroxide and superoxide scavenger that has no effect on phagocytosis or oxygen consumption by activated neutrophils but rather in their phagosome [76].

**Burkholderia cenocepacia infections**

*Burkholderia cenocepacia* infects patients with CF within their macrophages in membrane vacuoles that preclude fusion with the lysosome [77-80]. B. cepacia complex co-infects with *P. aeruginosa* reducing its biofilm capacity. *B. cenocepacia* and *B. multivorans* express mucinas that utilize mucin as carbon source and fermentation rather than anaerobic respiration to obtain energy [81]. *Burkholderia pseudomallei* is the causative agent of melioidosis characterized by pneumonia and fatal septicemia and a strong risk factors of mortality in CF [82].

**Mycobacterium abscessus infections**

*Mycobacterium abscessus* is a rapidly growing mycobacterial species that infects macrophages, and is an important pathogen in patients with CF [55]. Genome analysis of this bacterium showed its metabolic pathways typically found in environmental microorganisms.
that come into contact with soil, plants, and aquatic environments but also contains several genes that are characteristically found only in pathogenic bacteria. One of them is MAB_0555, encoding a putative phospholipase C (PLC) that is absent from most other rapidly growing mycobacteria, including Mycobacterium chelonae and Mycobacterium smegmatis. PLC is highly cytotoxic to mouse macrophages, presumably due to hydrolysis of membrane phospholipids. Using an M. abscessus PLC knockout mutant was shown that loss of PLC activity is deleterious to M. abscessus intracellular survival in amoebae [83]. This ability to survive intracellular in macrophages and neutrophils initiate the formation of cords that when released from apoptotic macrophages or neutrophil become too large to be phagocytized. Cords initiated in the vasculature enter the central nervous system producing abscesses in the brain of CF patients [84]. Aspergillus spp. are present in the airways of 2040% of CF patients and are of unclear clinical significance [31].

In addition to lung infections, patients with CF has reduced intestinal richness with decreased levels of Eubacterium rectale, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium catenulatum, and Faecalibacterium prausnitzii and increased levels of inflammation shown by higher fecal levels of calprotectin and rectal nitric oxide [85]. Stimulating the growth of species involved in immunity development, such as Bifidobacterium species, Sutterella wadsworthia, and Clostridium cluster XIVa organisms, and at the same time increased the production of butyrate and propionate seems to be possible to restore Th1 bias and INF-γ levels that improves bacterial clearance [86].

Treatments of CF disease

Antibiotics resistance of pathogens infecting CF patients is a hallmark of the disease. The use of phytochemicals to enhance bacterial susceptibility to antibiotic, like zingerone (active components from ginger) seem to increase the P. aeruginosa sensitivity to antibiotics by reducing its cell surface hydrophobicity, alginate and LPS production, thus increasing its phagocytic susceptibility by macrophages decreasing TNF-α and MIP-2 produced by them [87].

In addition, alterations of the intestinal microbiota impacts the systemic immune response, reports suggest that dietary acidic oligosaccharides can favor a Th1 immune response, restoring INF-α level in the lung and bacterial clearance [86].

Antibiotics therapy

The chronic bacterial infection found in the airways is a recurrent problem in the CF disease, particularly susceptible to Pseudomonas aeruginosa, which is by far the most significant pathogen responsible of morbidity and mortality [88]. Repetitive and prolonged infections allow the selection of hyper mutated strains of P. aeruginosa with antibiotic multiresistance to conventional therapies and able to persist for years in most patients [89]. Once the strain converts to mucoid phenotype, an exacerbation of alginate secretion is produced and thereby the strain becomes extremely difficult to eradicate. In the biofilm architecture, the microbiorganisms are capable to survive even under aggressive antibiotic treatments [90]. Thus, an early "antibiotic eradication therapy" is highly recommended in CF [91,92]. Undoubtedly, appropriate therapies and strict use of multi-antibiotic doses are responsible of life-quality improvement and increased survival of CF patients.

Nowadays, there is not a consensus among clinicians about the most adequate antibiotic treatment against P. aeruginosa [93]. Table 2 summarizes the antimicrobial agents commonly use and their recommended doses [93]. Many factors are influencing the efficiency of drug therapies but not only based on the antibiotic therapeutic properties but also considering other factors like molecular properties of drugs (e.g. chemical structure, functional active groups, solubility, biodisposition, target sites), the route of administration and importantly the formulation of therapeutic molecules.

Some microbial isolates from CF sputum were completely susceptible to antibiotics like: tobramycin, ceftazidime, colistin, imipenem, levofloxacin, and ciprofloxacin, and synergistic effects have been found with combination some of them [94]. The administration of inhaled antibiotics in addition to other antibiotics orally deliver in treatment for 3 weeks to 3 months has been used successfully [95]. A decrease in lung inflammation has been found in trial therapy with oral/inhaled antibiotic treatment in comparison with intravenous administration [96]. In fact, 3 months treatment with of high-doses of inhaled colistin combined with oral ciprofloxacin had produced the best therapeutic results in management of Pseudomonas aeruginosa infections [97].

Nano particles therapies

However, novel therapeutic alternatives are under intensive studies.

Table 2. Antibiotics dosages commonly used in the management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections (modified from Döring et al., 2000).

| Family         | Antibiotic     | Administration route | Number of administrations per day | Dose per day (mg/kg) |
|----------------|----------------|----------------------|-------------------------------|---------------------|
| Aminoglycosides| Amikacin       | i.v.                 | 2                             | 30                  |
|                | Tobramycin     | i.v.                 | 2                             | 10                  |
|                |               | inhaled              | 1-2                           | 150-300             |
|                | Netilmicin     | i.v.                 | 2                             | 10                  |
| Betalactamides | Aztreonam      | i.v.                 | 4                             | 150                 |
|                |               | i.v.                 |                               | 100                 |
|                |               | continuously         |                               | 100                 |
| Cephalosporins | Ceftazidime    | i.v.                 | 3-4                           | 100-150             |
|                |               | i.v.                 | 2-3                           | 100-150             |
|                | Ceftriaxone    | i.v.                 | 3-4                           | 150-250             |
|                |               | continuously         |                               | 100-150             |
| Quinolones     | Ciprofloxacin  | oral                 | 2-3                           | 30                  |
| Polymyxins     | Colistin       | inhaled              | 1-2                           | 80-160              |
| Carboxypenicillins | Ticaricilin   | i.v.                 | 4                             | 500-750             |
| Carapenem      | Meropenem      | i.v.                 | 3                             | 60-120              |
|                |               | continuously         |                               | 60                  |

i.v. = intravenous
to increase the effectiveness of conventional antibiotics and to overcome the resistant mechanism of microbial pathogens. In this sense, novel strategies are focus on the antibiotic encapsulation in nano- and micro-carriers to improve the antibiotic biodisponibility, and to provide a proper molecular control release profile under the therapeutic window, avoiding the use of high concentrations which results in undesirable hepatic- and nephro-toxicity side effects. Among them, quinolones and amikacin have been encapsulated in liposomal formulation or solid lipid nanoparticles for pulmonary delivery, improving the biodistribution of the antibiotics and the patients’ compliance [98]. Figure 4 shows images of amikacin loaded nanoparticles biodistribution in rats. However, the dynamic characteristics of liposomes and their intrinsic instability under different physicochemical environments do not allow predicting and determining the precise amount of delivered drug and their efficiency in the lungs. On the contrary, biopolymers are good alternative to make matrices for drug delivery since most of them are non-toxic, biodegradable, easily tailorable, and cheap. Also, biopolymer devices for drug delivery are advantageous since there are able make stable gel structures, can carry more than one therapeutic molecule, the amount of cargo/s can be very well-establish allowing to determine specific molecular kinetic release. For example, co-administration of quinolones and enzymes with complementary functions (such as alginase lyase or Dnase) encapsulated into biopolymer microspheres has been reported successful to decrease viscoelasticity of the purulent mucus and enhance the antibiotic efficiency [99,100]. The main advantage of combining antibiotics and hydrolytic enzymes are to increase not only the diffusivity of the antibiotic through the biofilms reaching the microbial cell surface more easily but also reducing the antibiotic dose. Also, the use of phytochemicals seems to enhance bacterial susceptibility to antibiotic and improve antibiofilm efficacy of ciprofloxacin against P. aeruginosa PAO1. Active components like zingerone (extracted from ginger) could increase the P. aeruginosa sensitivity to antibiotics by reducing its cell surface hydrophobicity and decreasing the alginate and LPS production. Consequently, there is an increase in its susceptibility to phagocytosis by macrophages decreasing the TNF-α and MIP-2 levels [86]. Other works reveal that extracts of garlic could act as anti-quorum sensing molecules, preventing biofilm formation, increasing the clearing of the infecting bacteria and potentiating the effect of tobramycin [101].

**Microbiome maintenance**

A relatively new research field is focus on the study of the lung and gastrointestinal microbiome of CF patients. Both microbiotas seem to be intrinsically influenced in such a way that the development and maintenance of lung immunity and inflammation are related with the intestinal microorganism [102]. It was observed a strong correlation between low species richness and poor lung function [103]. Studies revealed that microorganisms in the intestine will be playing an important function in regulating T helper cells, regulatory T cells and dendritic cells as well as Toll-like receptor expression in macrophage and dendritic cells, which are the key tools to combat bacterial infections [104,105].

Patients with CF have reduced intestinal richness with low levels of *Eubacterium rectale*, *Bacteroides uniformis*, *Bacteroides vulgatus*, *Bifidobacterium adolescentis*, *Bifidobacterium catenulatum*, and *Faecalibacterium prausnitzii*, and usually present a serious degree of inflammation which is reflected in the higher fecal levels of calprotectin and rectal nitric oxide [85].

An alternative to restore the balance of the microbiome is set by stimulation of the growth of species involved in immunity development, such as *Bifidobacterium* and *Lactobacillus* species, *Sutterella wadsworthia*, and *Clostridium* cluster XIVa organisms. Studies have demonstrated that prebiotics could stimulate the growth of bifidobacteria and lactobacilli, developing important immune-modulating functions in Th1 response and T cell regulation. Short chain galacto-oligosaccharides and long-chain fructo-oligosaccharides are included in these non-digestible carbohydrates group. At the same time, prebiotics can be degraded by the natural intestinal flora to produce short-chain fatty acids (such as butyrate and propionate) which could reactivate the Th1 bias by increasing TNF-α levels that improves bacterial clearance [106].

Studies in mice models indicate that pretreatment with pectin-derived acidic oligosaccharides may help to improve the incidence of *P. aeruginosa* pulmonary infection by increasing bacterial clearance with a shift in the Th1/Th2 balance toward a predominantly Th1 response [86].

Certainly, further studies will be necessary to explore the microbiome of different microbial communities in the airways and intestine of healthy and infected patients to elucidate the mechanisms involved in immunity and the relationship with strong antibiotics treatments [103].

**Dietary supplements**

Patients with CF need to follow a very strict diet according to the age and grade of illness, and therefore different nutrient requirements should be carefully monitored to guarantee a normal growth [107]. Due to the systemic mucus accumulated at different organs, clinical compliance is associated with malnutrition and poor absorption of foods in patients [108].

The Cystic Fibrosis Foundation highlights that patients treatment include the supplying of adequate calories, intake of sufficient vitamin D and K and specially incorporation of calcium enough to avoid pathologies like osteopenia and osteoporosis [109]. Table 3 shows the most relevant nutrients that patients need to take into account for a suitable nutrition.
One of the main causes of malnutrition in patients is due to a pancreatic insufficiency (PI). When PI is present, an active nutritional management is started by the addition of pancreatic enzymes to the diet. Preferably, enzymes are encapsulated in microspheres or microtablets, which provide them protection against the enteric acidity and prevent their rapid inactivation [107]. However, the enzymatic activities released in the intestine are not very efficient as it should be required by the pathology. A complementary strategy is based on the ingestion of prebiotics which have a positive impact in the restoration of a healthy microbiota at intestine and an enhancement of the systemic immune response is usually observed. Reports suggest that dietary acidic oligosaccharides can favor a Th1 immune response, restoring a health microbiota at intestine and an enhancement of the systemic immune response is usually observed. Reports suggest that dietary acidic oligosaccharides can favor a Th1 immune response, restoring INF-α level in the lung and bacterial clearance [86].

**Gene transfer**

The main focus for the next generation of therapeutics is based on the concepts of metabolic engineering by reprogramming cell and tissue metabolism and correcting metabolic deficiencies by changes in the somatic cell genomes using gene delivery technologies. In the last decades, different attempts have been focused on the restoration of the defective human cystic fibrosis transmembrane conductance regulator. Some experiments in transgenic mice have shown that the CFTR gen can be effectively transferred to epithelial cells of the lung. In addition, the mRNA of the gen could be found in bronchiolar and alveolar epithelial cells, while the CFTR protein in respiratory epithelial cells [110]. Similar works reported the possibility to directly transfer the normal CFTR gene to the airway epithelium by the use of a replication-deficient recombinant adenovirus vector containing the normal CFTR cDNA obtained interesting results in-vitro and in-vivo models [111]. After treatment, the absence of viral replication or virus-associated adverse effects opened a new window in the recovery of the CF lung function by gene therapy [112]. Figure 5 represents a scheme of the gene delivery by adenovirus.

In the following years, other methods for gene delivery have been explored such as fat capsules, synthetic vectors, nose drops or drizzling cells in addition to new aerosol methods using nebulizers. In this sense, novel strategies for gene therapy in CF disease are based on the discovery of more functional, effective and versatile gene delivery systems [113]. However, there is no a specific report of a gene delivery system that works properly for all kinds of cell types with no limitations or side effects. Some reviews describe in detail the different gene delivery systems for germline (like nuclei, egg cells, embryonic stem cells, pronuclear, microinjection and sperm cells) and somatic cells by the use of:

- Viral systems: such as retroviral, adenoviral, adeno-associated vectors, helper-dependent adenoviral systems, hybrid adenoviral systems, herpes simplex, pox virus, lentivirus, *Epstein–Barr virus*.

- Non-viral DNA based systems:
  - Physical: naked DNA, DNA bombardant, electroporation, hydrodynamic, ultrasound, magnetofection.
  - Chemical: cationic lipids, different cationic polymers, lipid polymers.

The selection of the adequate carrier will be restricted to the cell type, the target organ and the treatment duration [114,115]. Retroviral vectors are advantageous since they are integrating the selected recombinant genes by transduction. Particularly, lentivirus are preferred because of they are very stable vectors and able to transfect dividing and non-dividing cells by integrating the virus shell directly to the nucleus membrane of the cells. Besides, the main problem of lentivirus vectors are associated to the lack of surface proteins in the capsid for the recognition of respiratory epithelium receptors [116]. Also, quiescent cells are refractory to the vector because of G0 state in which the reverse transcription is blocked [117].

Alternatively, Sendai virus (SeV) originated from mouse parainfluenza virus type 1, were explored as potential therapeutic vectors. Among the advantages of Sendai vector is a cytoplasm RNA expression without the requirement of chromosomal integration, and also displaying high transfection efficiency in epithelial cells due to the sialic acid and cholesterol receptors [118].

Among the viral vector systems, adenoviruses were the first choice of candidates for CF gene therapy since the target is the respiratory epithelium. However, adenoviruses are strong inducers of immune response and also low transduction efficiency which are limiting the therapeutic use [116]. Adeno-associated viral are an alternative vectors because of extensive gene transfer and expression in non-human epithelia and lack of strong immune response [117]. Besides, the main limitation of Adeno-associated vectors is related to the large size of the CFTR cassette to be inserted in viral capsid. Other viral vectors were reported for cystic fibrosis therapy but most of them are unstable showing inactive recombinant forms, or very low infectivity.

Overall, the most viral vector systems are made to transfect CFTR-deficient cells which require repetitive administrations and causing both cellular and humoral responses concomitantly with the decrease of gene expression [118]. However, the main concern about gene

---

**Table 3.** Nutrients to be monitored for establish the nutritional status of CF patients (modified from Borowitz et al., 2002).

| Nutrient          | At diagnosis | Annual | Other               |
|-------------------|--------------|--------|---------------------|
| Vitamin A        | x            | x      |                     |
| Vitamin D        | x            | x      |                     |
| Vitamin E        | x            | x      |                     |
| Vitamin K        | x            | -      | Hemoptyis or hematemesis cases; liver disease |
| Essential fatty acids | -       | -      | Patients older than 8 years (risk cases) |
| Calcium          | -            | -      | Infants             |
| Iron             | x            | x      | Poor appetite and fatigue |
| Zinc             | -            | -      | Recommended 6 months supplementation and check changes in growth |
| Sodium           | -            | -      | Patients exposed to heat stress or dehydration |
| Protein stores   | X            | x      | Nutritional failure |
| Beta carotene    | -            | -      | Under criteria of the physician |

---

*Palm Crit Care Med, 2016*  
[10.15761/PCCM.1000110]  
Volume 1(2): 39-51
therapy is related to the safety. Viral vectors, particularly retrovirus, can elicit from mild acute inflammation to strong immune response that can compromise life. In addition, recombination events of the vector with potential wild-type viruses present in the patient can trigger unpredictable consequences [110].

Regarding to the non-viral gene therapies, up today the transfection strategies are very limited with poor efficiencies.

Conclusions

The cystic fibrosis transmembrane regulator mutations comprise a complex pathology involving many signaling pathways and organs. Present therapies depend of case and they are determined not only by the mutations but also physiological and nutritional conditions of the patients. Up today, the therapeutic procedures are palliatives trying to keep standard levels of life quality based on combination of strict medication and nutritional diets. Nanotechnology in these aspects can provide novel platforms to treat and prevent the physiological consequences of the CF pathology. Particularly, if the pathology can be diagnosed in the patients during the early stages and the gene therapy proceeds by restoring CFTR activity in immune cells can prevent the lung pathology as well as other diseases before overlooked, like diabetes, where the role of CFTR mutations also has a role. Gene delivery seems to be a strategic area to be considered for the development of novel CF therapeutic agents based on the recent contributions of biotechnology and nanotechnologies.

References

1. Lubamba B, Dhoooghe B, Noel S, Leal T (2012) Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem 45: 1132-1144. [Crossref]
2. Anonymous (2015) Understanding cystic fibrosis. American Lung Association.
3. Kleizen B, van Vlijmen T, de Jonge HR, Braakman I (2005) Folding of CFTR is predominantly cotranslational. Molecular Cell 20: 277-287.
4. Riordan JR (2005) Assembly of functional CFTR chloride channels. Annu. Rev. Physiol. 67: 701-718.
5. Ratjen F, Döiring G (2003) Cystic fibrosis. Lancet 361: 681-689. [Crossref]
6. Quinton PM (2008) Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 372: 415-417. [Crossref]
7. Cant N, Pollock N, Ford RC (2014) CFTR structure and cystic fibrosis. Int J Biochem Cell Biol 52: 15-25. [Crossref]
8. Butterworth MB (2010) Regulation of the epithelial sodium channel (ENaC) by membrane trafficking. Biochim Biophys Acta 1802: 243-251. [Crossref]
9. Egan ME, Schwiebert EM, Guggino WB (1995) Differential expression of ORCC and CFTR channel gating by AMP-activated protein kinase modulates cystic fibrosis therapy. J Biol Chem 270: 19551-19557. [Crossref]
10. Welling PA, Ho K (2009) A comprehensive guide to the ROMK potassium channel: form and function in health and disease. Am J Physiol Renal Physiol 297: F849-863. [Crossref]
11. Klein I, Sarkadi B, Váradi A (1999) An inventory of the human ABC proteins. Biochim Biophys Acta 1461: 237-262. [Crossref]
12. Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67-113. [Crossref]
13. Linsdell P (2006) Mechanism of chloride permeation in the cystic fibrosis transmembrane conductance regulator chloride channel. Exp Physiol 91: 123-129.
14. Vergani P, Lockless SW, Nairn AC, Gadsby DC (2005) CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 433: 876-880.
15. Guggino WB, Stanton BA (2006) New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat Rev Mol Cell Biol 7: 426-436. [Crossref]
16. Borthwick LA, McGaw J, Conner G, Taylor CJ, Gerke V, et al. (2007) The Formation of the cAMP/Protein Kinase A-dependent Annexin 2 S100A10 Complex with Cystic Fibrosis Conductance Regulator Protein (CFTR) Regulates CFTR Channel Function. Molecular Biology of the Cell 18: 3388-3397.
17. Hallows KR, McCane JE, Kemp BE, Witters LA, Foskett JK (2003) Regulation of channel gating by AMP-activated protein kinase modulates cystic fibrosis transmembrane conductance regulator activity in lung submucosal cells. The Journal of Biological Chemistry 278: 998-1004.
18. Luo J, Pato MD, Riordan JR, Hanrahan JW (1998) Differential regulation of single CFTR channels by PP2C, PP2A, and other phosphatases. Am J Physiol 274: C1397-1410. [Crossref]
19. Chang SY, Di A, Naren AP, Palfrey HC, Kirk KL, et al. (2002) Mechanisms of CFTR
regulation by syntaxin 1A and PKA. J Cell Sci 115: 783-791. [Crossref]

20. Li C, Krishnamurthy PC, Pennnata H, Marrs KL, Wang XQ, et al. (2007) Spatiotemporal coupling of Camp sensor to CFTR chloride channel function in the gut epithelia. Cell 131: 940-951. [Crossref]

21. Li C, Dandridge KS, Di A, Marrs KL, Harris EL, et al. (2005) Lysoosphosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions. The Journal of Experimental Medicine 202: 975-986.

22. Raghammer V, Mak DO, Fossett JK (2001) Regulation of cystic fibrosis transmembrane conductance regulator single-channel gating by bivalent PDZ domain-mediated interaction. Proc Natl Acad Sci USA 98: 1300-1305.

23. Meacham GC, Patterson C, Zhang W, Younger JM, Cyr DM (2001) The Hdc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol 3: 100-105.

24. Lederkerner GZ (2009) Glycoprotein folding, quality control and ER-associated degradation. Current Opinion in Structural Biology 19:515-523.

25. Liedtke CM, Yun CH, Kyle N, Wang D (2002) Protein kinase C epsilon-dependent regulation of cystic fibrosis transmembrane regulator involves binding to a receptor for activated C kinase (RACK1) and RACK1 binding to Na+/H+ exchange regulatory factor. The Journal of Biological Chemistry 277: 22925-22933.

26. Auerbach M, Liedtke CM (2007) Role of the scaffold protein RACK1 in apical expression of CFTR. Am J Physiol Cell Physiol 293: C294-304. [Crossref]

27. Chan VR, K Chen, SR Duncan, KL Labthrop, JD Latoche, et al. (2013) Patients with cystic fibrosis have inducible IL-17+IL-22+ memory cells in lung draining lymph nodes. J Allergy Clin Immunol 131: 1127-29.

28. Newcomb DC, Boswell MG, Zhou W, Huckabee MM, Goleniewska K, et al. (2011) Transferrin receptor-dependent expression of CFTR. J Allergy Clin Immunol 127: 1006-1013. [Crossref]

29. Anil N, Singh M (2014) CD4(+)CD25(high) FOXP3(+) regulatory T cells correlate with FEV1 in North Indian children with cystic fibrosis. J Allergy Clin Immunol Invest 43: 553-543. [Crossref]

30. Hector A, Scha fer H, Po schel S, Fischer A, Fritzsching B, et al. (2015) Regulatory T cell impairment in cystic fibrosis patients with chronic pulmonary infections. Am J Respir Crit Care Med 191: 9143-2.

31. Allard JB, Poynter ME, Marr KA, Cohn L, Rincon M, et al. (2006) Aspergillus fumigatus generates an enhanced Th2biased immune response in mice with defective cystic fibrosis transmembrane conductance regulator. J Immunol 177: 518694.

32. Mueller C, Boswell MG, Zhou W, Huckabee MM, Goleniewska K, et al. (2011) Human TH17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production. J Allergy Clin Immunol 127: 1006-1013. [Crossref]

33. Anil N, Singh M (2014) CD4(+)(CD25(high)) (FOXP3(+)) regulatory T cells correlate with FEV1 in North Indian children with cystic fibrosis. Immunol Invest 43: 553-543. [Crossref]

34. Auerbach M, Liedtke CM (2007) Role of the scaffold protein RACK1 in apical expression of CFTR. Am J Physiol Cell Physiol 293: C294-304. [Crossref]

35. Tu J, Le XY, Ballard HJ (2010) Involvement of the cystic fibrosis transmembrane conductance regulator in the acidosis-induced efflux of ATP from rat skeletal muscle. J Physiol 588: 4563-4578.

36. Vanderstocken G, Van de Paer E, Robaye B, di Pietranantonio L, Bondue B, et al. (2012) Protective role of P2Y2 receptor against lung infection induced by pneumonia virus of mice. PLoS One 7: e50385.

37. Kushwah R, Gagnon S, Sweezy NB (2013) Intrinsic predisposition of naive cystic fibrosis T cells to differentiate towards a Th17 phenotype. Respire Res 14: 138. [Crossref]

38. Fukahori S, Matsuse H, Tsuchida T, Kawano T, Nishino T, et al. (2014) Clearance of Burkholderia cenocepacia in human cystic fibrosis macrophages via interleukin 6. Biochemie 107: 95104.

39. Gao Z, Su X (2015) CFTR regulates acute inflammatory responses in macrophages. QJM 108: 951-958. [Crossref]

40. Zhang PX, Cheng J, Zou S, D’Souza AD, Koff JL, et al. (2015) Pharmacological modulation of the AKT/microRNA-19a-5p-CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation. Nat Commun 6: 6221. [Crossref]

41. Cremer TJ, Shah P, Cornet Boyaka E, Valvano MA, Butchar JP, et al. (2011) Akt-mediated proinflammatory response of mononuclear phagocytes infected with Burkholderia cenocepacia occurs in a novel GSK3B-dependent, 70kidasine-dependent mechanism. J Immunol 187: 63543.

42. Zaghair SM, Stauffer BB, McCarthy NA (2014) Inflammation and ER stress downregulate BIDH2 expression and dysregulate intracellular iron in macrophages. J Immunol Res 2014: 140728. [Crossref]

43. Grassme H (2000) CD95/CD95 ligand interactions on epithelial cells in host defense against Pseudomonas aeruginosa. Science 290: 527-530.

44. Yoshida M, Xia Y (2003) Heat shock protein 90 as an endogenous protein enhancer of inducible nitric-oxide synthase. J Biol Chem 278: 36953-36958. [Crossref]

45. Zhang Y, Li X, Carpinteiro A, Goettel JA, Siddemman M, et al. (2011) Kinase suppressor of Ras-1 protects against pulmonary Pseudomonas aeruginosa infections. Nat Med 17: 341-346. [Crossref]

46. Abdalla MY, Ahmad IM, Switzer B, Britigan BE (2015) Induction of heme oxygenase-1 contributes to survival of Mycobacterium abscessus in human macrophages-like THP-1 cells. Redox Biol 4: 328-339. [Crossref]

47. Biswal S, Thimmulappa RK, Harvey CJ (2012) Experimental therapeutics of Nrf2 as a target for prevention of bacterial exacerbations in COPD. Proc Am Thorac Soc 9: 47-51. [Crossref]

48. Grumelli S, Corry DB, Song LZ, Song L, Green L, et al. (2004) An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 1: e8.

49. Trojanik JB, CobosCorrea A, Diemer S, Kormann M, Schubert SC, et al. (2014) Airway mucus obstruction triggers macrophage activation and matrix metalloproteinase-12dependent emphysema. Am J Respir Cell Mol Biol 51: 70926.

50. Woods PS, Tazi MF, Chesarino NM, Akeroyd AM, Davis IC (2015) TGF-β1-induced IL-6 prevents development of acute lung injury in influenza A virus-infected F508del-CFTR-heterozygous mice. Am J Physiol Lung Cell Mol Physiol 308: L1136-1144. [Crossref]

51. Pereira LC, Moreira EA, Bennemann GD, Moreno YM, Buss Zda S, et al. (2014) Influence of inflammatory response, infection, and pulmonary function in cystic fibrosis. Life Sci 109: 306.

52. Bratcher PE, Rowe SM, Reeves G, Roberts T, Szul T, et al. (2016) Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor. J Cyst Fibros 15: 67-73. [Crossref]

53. Fritzsching B, ZhouSuckow Z, Trojanik JB, Schubert SC, Skathtery J, et al. (2015) Hypoxic Epithelial Necrosis Triggers Neurophilic Inflammation via IL1Receptor Signaling in Cystic Fibrosis Lung Disease. Am J Respir Crit Care Med 191: 90213.
Grumelli S (2016) Consequences of cystic fibrosis transmembrane regulator mutations on inflammatory cells.
106. Smith PM, Howitt MR, Panikov N (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* 341:569-73.

107. Ramsey BW, Farrell PM, Pencharz P (1992) Nutritional assessment and management in cystic fibrosis: a consensus report. The Consensus Committee. *The American Journal of Clinical Nutrition* 55: 108-116.

108. Becker LT, Russel-Cohen E, Fink RJ (2001) Stature as a prognostic factor in cystic fibrosis survival. *J Am Diet Assoc* 101: 438-442. [Crossref]

109. Borowitz D, Baker RD, Stallings V (2002) Consensus report on nutrition for pediatric patients with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 35: 246-259. [Crossref]

110. Whitsett JA, Dey CR, Stripp BR, Wikenheiser KA, Clark JC, et al. (1992) Human cystic fibrosis transmembrane conductance regulator directed to respiratory epithelial cells of transgenic mice. *Nature Genetics* 2: 13-20.

111. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, et al. (1992) In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. *Cell* 68: 143-155. [Crossref]

112. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, et al. (1993) Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. *Cell* 75: 207-216.

113. Klink D, Schindelhauer D, Laner A, Tucker T, Bebok Z, et al. (2004) Gene delivery systems-gene therapy vectors for cystic fibrosis. *Journal of Cystic Fibrosis* 3: 203-212.

114. Sinn PL, Anthony RM, McCray PB Jr (2011) Genetic therapies for cystic fibrosis lung disease. *Hum Mol Genet* 20: R79-86. [Crossref]

115. Nayerossadat N, Maede T, Ali PA (2012) Viral and nonviral delivery systems for gene delivery. *Adv Biomed Res* 1: 27. [Crossref]

116. John G, Chilappagari S, Rubin BK, Gruenert DC, Henke MO (2011) Reduced surface tolllike receptor4 expression and absent interferon7 inducible protein10 induction in cystic fibrosis airway cells. *Exp Lung Res* 37: 31926.

117. Kumar L, Chhibber S, Harjai K (2014) Structural alterations in Pseudomonas aeruginosa by zingerone contribute to enhanced susceptibility to antibiotics, serum and phagocytes. Life Sci 117: 24-32. [Crossref]

118. Thursfield RM, Davies JC (2012) Cystic Fibrosis: therapies targeting specific gene defects. *Paediatric Respiratory Reviews* 13: 215-219.